Trials / Completed
CompletedNCT00090090
Elsamitrucin (SPI 28090) for Relapsed or Refractory Non-Hodgkin's Lymphoma
A Multi-Center, Open-Label, Non-Randomized Phase II Study of Elsamitrucin (SPI 28090) In Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 114 (planned)
- Sponsor
- Spectrum Pharmaceuticals, Inc · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To determine the safety and efficacy of elsamitrucin in patients with relapsed or refractory non-Hodgkin's lymphoma (NHL). To determine if elsamitrucin is efficacious in a particular pathologic NHL subtype(s).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Elsamitrucin |
Timeline
- Start date
- 2004-04-01
- Completion
- 2006-10-01
- First posted
- 2004-08-25
- Last updated
- 2008-01-15
Locations
7 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00090090. Inclusion in this directory is not an endorsement.